Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review. (PubMed, Neurol Ther) - Oct 10, 2026 - "Observational studies in MS suggest that EID of ocrelizumab and rituximab may maintain short-term clinical and radiological disease control in selected stable patients while potentially reducing immunoglobulin decline and improving vaccine responsiveness. By contrast, anti-CD20 efficacy in MOGAD appears less consistent, whereas in autoimmune encephalitis rituximab is particularly effective in antibody-mediated disease associated with neuronal surface antigens. Overall, strategies to reduce cumulative anti-CD20 exposure represent a promising direction for long-term treatment optimization, although prospective randomized studies are still needed to define the safest and most effective dosing approaches."
Journal • Review • CNS Disorders • Immunology • Infectious Disease • Inflammation • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases • Solid Tumor
|
|
Alessandro Dinoto; Assunta Bianco; Claudio Procaccini; Diana Ferraro; Diego Centonze; Elisabetta Signoriello; Federica Azzolini; Gabriela Constantin; Gabriele Di Sante; Gianmarco Abbadessa; Giorgia Teresa Maniscalco; Massimiliano Di Filippo; Raffaele Iorio; Roberta Magliozzi; Rosella Mechelli; Sara Carta; Sara Mariotto
|